Sacubitril/ Valsartan wasn't effective in controlling heart attack comparing to ramipril: PARADISE MI Trial

Written By :  MD Editorial Team
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-02-23 03:30 GMT   |   Update On 2023-10-13 09:59 GMT
Advertisement

Myocardial infarction, commonly called a heart attack is an extremely dangerous condition caused by a lack of blood flow to your heart muscle. The lack of blood flow can occur because of many different factors but is usually related to a blockage in one or more of arteries. The chest pain is often severe, but some people experience minor pain, similar to indigestion.

The PARADISE-MI trial showed that sacubitril/valsartan did not reduce the primary endpoint in a contemporary enriched AMI population, compared with ramipril.

Advertisement

The trial is published in American College of Cardiology journal.

The trial assesses the efficacy and safety of sacubitril/valsartan compared with ramipril in a contemporary acute myocardial infarction population. Eligible patients were randomized in a 1:1 fashion where 2,830 in sacubitril/valsartan (target dose 97/103 mg twice a day) or 2,831 ramipril (target 5 mg twice a day).

The primary outcome of cardiovascular (CV) death, first Heart Failure (HF) hospitalization, or outpatient Heart Failure for sacubitril/valsartan vs. ramipril, was: 11.9% vs. 13.2%. CV death: 5.9% vs. 6.7% (p = 0.20); HF hospitalization was 6% vs. 6.9% (p = 0.17). Secondary outcomes for sacubitril/valsartan vs. ramipril showed CV death/MI/stroke: 11.1% vs. 12.3% (p = 0.18). All-cause mortality was also 7.5% vs. 8.5% (p = 0.16). Total HF hospitalization, outpatient HF events, and CV mortality: 8.4 vs.10.1/100 patient-years (p = 0.02). Hypotension: 28.4% vs. 22.0% (p < 0.05).

The results of this trial indicate that the combination sacubitril/valsartan did not reduce the primary endpoint in a contemporary enriched acute myocardial infarction population, compared with ramipril. These are interesting findings and add to the available data with angiotensin receptor-neprilysin inhibitors.

Reference: https://www.acc.org/latest-in-cardiology/clinical-trials/2021/05/14/01/22/paradise-mi

Tags:    
Article Source : American College of Cardiology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News